Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?

References

• Burnett A, Wetzler M, Löwenberg B. Therapeutic Advances in Acute Myeloid Leukemia. J Clin Oncol 2011;29(5):487-94
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115(3):453-74
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368(22):2059-74
   PubMed Web of Science ®Google Scholar
• Ben-Batalla I, Schultze A, Wroblewski M, et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood 2013;122(14):2443-52
   PubMed Web of Science ®Google Scholar
• Park IK, Mishra A, Chandler J, et al. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. Blood 2013;121(11):2064-73
   PubMed Web of Science ®Google Scholar
• Whitman SP, Kohlschmidt J, Maharry K, et al. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia 2014;28(6):1252-8
   PubMedGoogle Scholar
• O’bryan JP, Frye RA, Cogswell PC, et al. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 1991;11(10):5016-31
   PubMed Web of Science ®Google Scholar
• Janssen JW, Schulz AS, Steenvoorden AC, et al. A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 1991;6(11):2113-20
   PubMed Web of Science ®Google Scholar
• Schmidt T, Ben-Batalla I, Schultze A, Loges S. Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands. Cell Mol Life Sci 2012;69(9):1391-414
   PubMedGoogle Scholar
• Lew ED, Oh J, Burrola PG, et al. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities. Elife 2014;3
   PubMed Web of Science ®Google Scholar
• Rochlitz C, Lohri A, Bacchi M, et al. Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 1999;13(9):1352-8
   PubMed Web of Science ®Google Scholar
• Neubauer A, Burchert A, Maiwald C, et al. Recent progress on the role of Axl, a receptor tyrosine kinase, in malignant transformation of myeloid leukemias. Leuk Lymphoma 1997;25(1-2):91-6
   PubMed Web of Science ®Google Scholar
• Holland SJ, Pan A, Franci C, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 2010;70(4):1544-54
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Secreto C, Boysen J, et al. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood 2011;117(6):1928-37
   PubMed Web of Science ®Google Scholar
• Lee-Sherick AB, Eisenman KM, Sather S, et al. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene 2013;32(46):5359-68
   PubMed Web of Science ®Google Scholar
• Waizenegger JS, Ben-Batalla I, Weinhold N, et al. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma. Leukemia 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Boysen J, Sinha S, Price-Troska T, et al. The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients. Leukemia 2014;28(2):451-5
   PubMed Web of Science ®Google Scholar
• Linger RM, Cohen RA, Cummings CT, et al. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene 2013;32(29):3420-31
   PubMedGoogle Scholar
• Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012;44(8):852-60
   PubMed Web of Science ®Google Scholar
• Brand TM, Iida M, Stein AP, et al. AXL Mediates Resistance to Cetuximab Therapy. Cancer Res 2014;74(18):5152-64
   PubMed Web of Science ®Google Scholar
• Bosurgi L, Bernink JH, Delgado Cuevas V, et al. Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer. Proc Natl Acad Sci USA 2013;110(32):13091-6
   PubMed Web of Science ®Google Scholar
• Scott RS, Mcmahon EJ, Pop SM, et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 2001;411(6834):207-11
   PubMed Web of Science ®Google Scholar
• Wnuk-Lipinska K, Tiron C, Gausdal G, et al. BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies. American Association for Cancer Research - Annual Meeting 2014
   Google Scholar
• Leconet W, Larbouret C, Chardes T, et al. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene 2014;33(47):5405-14
   PubMed Web of Science ®Google Scholar
• Ye X, Li Y, Stawicki S, et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 2010;29(38):5254-64
   PubMed Web of Science ®Google Scholar
• Kariolis MS, Miao YR, Jones DS2nd, et al. An engineered Axl ‘decoy receptor’ effectively silences the Gas6-Axl signaling axis. Nat Chem Biol 2014;10(11):977-83
   PubMedGoogle Scholar